SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is surging as the company smashed earnings expectations, canceled a planned stock dilution, and projected aggressive revenue growth well above analyst estimates. The community is focused on the massive order backlog and robust profitability, leading many to call for a significant short squeeze.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is generating intense market activity as investors weigh anticipation for earnings against a high-profile, public short position that has become a major talking point. The community is focused on how the company's AI cloud infrastructure expansion and recent sector-wide tailwinds will influence its upcoming financial report.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors monitor upcoming leadership appearances at a major industry conference, fueling community anticipation for potential updates on the Alloy Kore platform. The discussion is centered on the company's long-term potential in software-defined vehicles and physical AI, even as market participants actively debate recent price action and institutional accumulation.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending following a strong quarterly earnings report that featured a massive revenue backlog and raised full-year guidance, fueling community optimism about the persistent demand for AI infrastructure. While bulls are celebrating the growth trajectory and potential for a short squeeze, skeptics remain vocal regarding the company's significant debt load, negative cash flow, and high capital expenditure requirements.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas is trending due to significant momentum from new contract wins, including a high-profile agreement with the Israeli Ministry of Defense, which is fueling intense community focus ahead of upcoming earnings. The stock is currently a major point of discussion for its extremely high short interest, with retail investors eagerly betting on a potential short squeeze as they analyze the company's aggressive acquisition strategy and its expanding footprint in the autonomous drone and defense sectors.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is trending as investors react to a robust quarterly earnings report and upward-revised guidance, fueling community debate over the stock's valuation versus its strong AI-driven demand. Discussions are heavily focused on the stock's ability to maintain its growth trajectory amidst broader sector volatility and high options activity.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as retail investors debate the stock's bottom, with many pointing to recent insider buying and long-term potential in AI infrastructure and 6G development as reasons to hold despite recent downward volatility. Sentiment remains sharply divided, with bulls viewing the current price as an attractive entry for long-term growth while bears express frustration over the ongoing sell-off and perceived market manipulation.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently under significant pressure following a pessimistic analyst downgrade and a sharp decline from sector peer On Holdings, leading many in the community to weigh in on whether the stock is a deep-value turnaround opportunity or a permanent value trap. While retail investors remain divided between frustrated bagholders venting about the long-term downtrend and bottom-fishers accumulating shares near current support, the primary talking points remain the company's China market reset, executive leadership changes, and a intense debate over whether the brand's competitive dominance in sports can outweigh its struggles with recent consumer demand.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company’s ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is seeing significant investor attention driven by a strong consensus of 'Strong Buy' ratings from analysts, who cite durable branded product growth and multiple upcoming catalysts like the QUELL trial readout for IHEEZO. Community discussion remains focused on the company's aggressive commercial scaling and the potential for long-term operational leverage as the product portfolio continues to expand.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is drawing significant market interest as investors monitor the imminent results of the REGAL Phase 3 trial, with the community actively speculating on the timing of the 80th event trigger and the implications of a self-imposed quiet period. The stock remains a focus for those betting on a potential oncology breakthrough or M&A activity, with discussions centered on the robust cash position and the expanding pipeline of SLS009.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Outlook Therapeutics, Inc. (OTLK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

Lexicon (LXRX) delivered earnings and revenue surprises of 0.00% and -88.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline

Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer

Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer...

Ovid Therapeutics (OVID) to Release Earnings on Tuesday

Ovid Therapeutics (NASDAQ:OVID) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...

Ovid Therapeutics (NASDAQ:OVID) Sees Large Decline in Short Interest

Ovid Therapeutics (NASDAQ:OVID - Get Free Report) saw a significant decline in short interest during the month of April. As of April 15th, there was short interest totaling 6,957,013 shares, a decline of 25.5% from the March 31st total of 9,337,824 shares. Based on an average trading volume of...

Ovid Therapeutics (NASDAQ:OVID) Given Average Recommendation of "Buy" by Analysts

Shares of Ovid Therapeutics (NASDAQ:OVID - Get Free Report) have been assigned an average rating of "Buy" from the ten research firms that are covering the firm, MarketBeat.com reports. One research...

Ovid Therapeutics' (OVID) "Outperform" Rating Reiterated at Wedbush

Wedbush reiterated an "outperform" rating and issued a $7.00 price target on shares of Ovid Therapeutics in a report on Wednesday...

Short Interest in Ovid Therapeutics (NASDAQ:OVID) Increases By 71.2%

Ovid Therapeutics (NASDAQ:OVID - Get Free Report) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totaling 9,337,824 shares, an increase...

HC Wainwright Issues Positive Forecast for OVID Earnings

Ovid Therapeutics (NASDAQ:OVID - Free Report) - Equities research analysts at HC Wainwright boosted their Q2 2026 earnings per share (EPS) estimates for Ovid Therapeutics in a research note issued on...

Ovid Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering better, gentler medicines for the brain. It discovers and develops differentiated, small molecule medicines for neurological and neuropsychiatric disorders with significant unmet need. The company was founded by Matthew During and Jeremy M. Levin on April 1, 2014 and is headquartered in New York, NY.

Ovid Therapeutics Inc

Ovid Therapeutics Stock Rallied 18% Pre-Market – Here’s Why

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$2.58
Prev Close	$2.62
Open	$2.62
Dividend Yield	0.00%
50-Day Moving Average	$2.46
Beta	1.10
Avg. Volume	1.64M
PE Ratio	-10.61

52-Week High	$3.11
52-Week Low	$0.55
Market Capitalization	$489M
EPS (Annual)	-$0.2362
Price to Book	2.18
Revenue Per Employee	$315,304.35

Feed

News

Sentiment

Earnings

Fundamentals

Info